一、关于 2023 年半年度控股股东及其他关联方占用公司资金及对外担保情 况的专项说明和独立意见 根据中国证券监督管理委员会《上市公司监管指引第 8 号—上市公司资金往 来、对外担保的监管要求》，我们本着对公司、全体股东负责的态度，对 2023 年半年度控股股东及其他关联方占用公司资金和对外担保情况进行了认真的检 查和落实，发表如下专项说明和独立意见： （一）报告期内，公司不存在控股股东及其他关联方占用公司资金的情形， 公司与其他关联方发生的关联资金往来均属于正常的非经营性资金往来，也不存 在以前期间发生并延续到报告期的控股股东及其他关联方占用公司资金的情况。 天水众兴菌业科技股份有限公司独立董事 关于第四届董事会第二十四次会议相关事项的独立意见 作为天水众兴菌业科技股份有限公司（以下简称"公司"）的独立董事，我 们根据中国证券监督管理委员会《上市公司独立董事规则》、《深圳证券交易所 上市公司自律监管指引第 1 号——主板上市公司规范运作》、《公司章程》及《独 立董事工作制度》等的相关规定，本着对公司、全体股东负责的态度，基于独立 的判断立场，秉承实事求是的原则，在仔细阅读相关材料后发表如下意见： 独立董事： ...

股票代码：002772 股票简称：众兴菌业 债券代码：128026 债券简称：众兴转债 公告编号：2023-053 天水众兴菌业科技股份有限公司 第四届董事会第二十四次会议决议公告 本次会议的召开程序符合《公司法》等法律法规和《公司章程》等的有关规 定。 二、董事会会议审议情况 经与会董事认真审议，本次会议以记名投票表决方式表决通过了以下议案： （一）审议通过了《关于公司<2023 年半年度报告全文及摘要>的议案》 根据法律法规、中国证券监督管理委员会及深圳证券交易所的相关规定和 《公司章程》等的相关要求，公司董事会编制了2023年半年度报告及其摘要。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 天水众兴菌业科技股份有限公司（以下简称"公司"）第四届董事会第二十 四次会议于 2023 年 08 月 18 日上午在公司会议室以现场结合通讯的方式召开。 本次会议由公司董事长高博书先生主持，会议通知已于 2023 年 08 月 07 日以电 子邮件方式送达给全体董事和高级管理人员。本次会议应出席董事 9 人，实际出 席董事 9 人（其中， ...

2023年半年度募集资金存放与使用情况公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 天水众兴菌业科技股份有限公司（以下简称"公司"）董事会根据中国证券监 督管理委员会《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要 求》（2022 年修订）及《深圳证券交易所上市公司自律监管指引第 1 号—主板上市 公司规范运作》等的相关规定，编制了《2023 年半年度募集资金存放与使用情况的 专项报告》。2023 年 08 月 18 日，公司召开第四届董事会第二十四次会议审议通过 了《关于<2023 年半年度募集资金存放与使用情况的专项报告>的议案》，公司监事 会、独立董事对该报告发表了明确同意的审核意见，具体情况如下： 股票代码：002772 股票简称：众兴菌业 债券代码：128026 债券简称：众兴转债 公告编号：2023-056 天水众兴菌业科技股份有限公司 一、募集资金基本情况 经中国证券监督管理委员会《关于核准天水众兴菌业科技股份有限公司公开发 行可转换公司债券的批复》（证监许可【2017】2002 号）核准，公司于 2017 年 12 月 ...

| 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司 | 上市公司核算的 | 2023年初占用资 | 2023年半年度往来累计发 | 2023年半年度占用资金 | 2023年半年度偿 | 2023年6月30日占 | 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 的关联关系 | 会计科目 | 金余额 | 生金额（不含利息） | 的利息（如有） | 还累计发生额 | 用资金余额 | | | | 控股股东、实际控制人及其 | | | | | | | | | | | | 附属企业 | | | | | | | | | | | | 小 计 | —— | —— | —— | | | | | | —— | —— | | 前控股股东、实际控制人及 | | | | | | | | | | | | 其附属企业 | | | | | | | | | | | | 小 计 | —— | —— | —— | | | | | | —— | —— | | 其他关联方及附属企业 | | | | | | | ...

天水众兴菌业科技股份有限公司 第四届监事会第十五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 | | | 1 / 2 一、监事会会议召开情况 天水众兴菌业科技股份有限公司（以下简称"公司"）第四届监事会第十五 次会议于 2023 年 08 月 18 日下午在公司会议室现场召开。召开本次会议的通知 已于 2023 年 08 月 07 日以电子邮件方式送达各位监事。 本次会议由监事会主席张天荣先生主持，会议应出席监事3名，实际出席3 名。会议召开程序符合《公司法》和《公司章程》等的有关规定。 二、监事会会议审议情况 经与会监事认真审议，本次会议以记名投票表决方式表决通过了以下议案： （一）审议通过了《关于公司<2023 年半年度报告全文及摘要>的议案》 表决情况：3 票同意、0 票反对、0 票弃权、0 票回避 表决结果：通过 监事会认为：董事会编制和审核公司《2023 年半年度报告》的程序符合法 律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司的 实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏，同意通过该报告并 签署了书 ...

天水众兴菌业科技股份有限公司（以下简称"公司"）于 2023 年 08 月 11 日收到公司持股 5%以上股东田德先生的告知函，获悉田德先生将其持有的公司 部分股份办理了解除质押及质押展期业务，现将具体情况公告如下： | 股票代码：002772 | 股票简称：众兴菌业 | 公告编号：2023-052 | | --- | --- | --- | | 债券代码：128026 | 债券简称：众兴转债 | | 天水众兴菌业科技股份有限公司 关于持股 5%以上股东部分股份解除质押及质押展期的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、股东股份质押基本情况 （一）本次股东股份解除质押情况 | 股东 | 是否为控股股东 或第一大股东及 | 本次解除质押 股份数量 | 占其所持 | 占公司总 | 质押起始日 | 质押解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | | | 股份比例 | 股本比例 | | | | | | 其一致行动人 | （股） | | | | | | | ...

股票代码：002772 股票简称：众兴菌业 债券代码：128026 债券简称：众兴转债 天水众兴菌业科技股份有限公司 投资者关系活动记录表 编号：2023-002 特定对象调研 □分析师会议 □媒体采访 业绩说明会 | --- | --- | --- | |--------------|-----------------------|--------------------------------------------------| | 投资者关系 | □新闻发布会 □路演活动 | | | | | | | 活动类别 | □现场参观 | | | | | 其他（深圳证券交易所"踔厉奋发新征程 投教服务再 | | | | 出发"主题投教活动走进上市公司--众兴菌业） | | | | 中国证监会投资者保护局、深圳证券交易所、甘肃证监 | | 活动参与人员 | | | | | 局、西部证券及 20 | 余名中小投资者。 | 时 间 2023 年 06 月 13 日 14:30 至 16:00 地 点 众兴菌业杨陵基地 形 式 现场 上市公司接待人员 公司董事长；董事会秘书及杨陵基地负责人。 问题 1：贵公司产品主要以 ...

股票代码：002772 股票简称：众兴菌业 债券代码：128026 债券简称：众兴转债 公告编号：2023-036 天水众兴菌业科技股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 天水众兴菌业科技股份有限公司 2023 年第一季度报告 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减（%） | | --- | --- | --- | --- | | 营业收入（元） | 622,909,683.16 | 488,191,571.56 | 27.60% | | 归属于上市公司股东的净利润 | 198,10 ...

Group 1: Company Overview - Stock code: 002772, Stock abbreviation: Zhongxing Junye [1] - Bond code: 128026, Bond abbreviation: Zhongxing Convertible Bond [1] - Company name: Tianshui Zhongxing Junye Technology Co., Ltd. [2] Group 2: Investor Relations Activity - Activity date: March 28, 2023, from 15:00 to 17:00 [2] - Format: Conducted via online remote method [2] - Participants included the Chairman, CFO, independent director, and board secretary [2] Group 3: Key Financial Performance - 2022 revenue: 1,970.27 million CNY, a year-on-year increase of 26.61% [4] - 2022 net profit attributable to shareholders: 158.35 million CNY, a year-on-year increase of 188.08% [4] Group 4: Research and Development - R&D personnel count decreased from 180 in 2021 to a lower number in 2022 due to the exclusion of auxiliary staff [3] - Future R&D focus includes "bottleneck" projects and improvement of cultivation technology [3] Group 5: Market and Product Insights - The company is involved in the factory production of edible mushrooms, utilizing AI technology in certain production processes [3] - Current cash on hand: 1.326 billion CNY, primarily for debt repayment and operational turnover [4] - The North Cordyceps project is in small-scale trial production [4] Group 6: Competitive Landscape - The company faces competition in the golden needle mushroom sector but operates mainly in the northern region, while competitors are more concentrated in the south [5] - The market for edible mushrooms is expanding due to increasing health awareness among consumers [5] Group 7: Future Plans and Strategies - The company aims to explore new profit growth points and is considering external acquisitions [4] - Plans for 2023 include focusing on operational stability and healthy development [6] - The company is exploring new sales channels to adapt to market demands [8]

Financial Performance - The company reported a cash dividend of 3.00 RMB per 10 shares for the 2022 fiscal year, maintaining the same distribution ratio as previous years[6]. - The company's operating revenue for 2022 was CNY 1,970,274,412.53, representing a 26.61% increase compared to CNY 1,556,146,725.49 in 2021[18]. - Net profit attributable to shareholders for 2022 was CNY 158,351,860.28, a significant increase of 188.08% from CNY 54,968,005.10 in 2021[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 179,126,371.50, up 480.39% from CNY 30,863,203.78 in 2021[18]. - The net cash flow from operating activities reached CNY 493,702,411.60, a turnaround from a negative cash flow of CNY -413,681,209.90 in 2021, marking a 219.34% increase[18]. - Basic and diluted earnings per share for 2022 were both CNY 0.40, reflecting a 185.71% increase from CNY 0.14 in 2021[18]. - Total assets at the end of 2022 were CNY 6,569,141,307.16, a slight increase of 0.27% from CNY 6,551,297,202.04 at the end of 2021[18]. - The net assets attributable to shareholders at the end of 2022 were CNY 3,381,602,576.16, up 4.09% from CNY 3,248,600,124.87 at the end of 2021[18]. - The company achieved a gross profit margin of 25.45% in the agricultural planting industry, up from 18.51% in the previous year, indicating a 6.94% increase[64]. - The company reported a total investment commitment of 90,290,000 CNY for various projects, with a cumulative investment of 56,465,000 CNY as of the reporting date[94]. Business Operations - The company operates in the agricultural technology sector, specifically focusing on edible fungi, with no changes in its main business since its listing[17]. - The company has not undergone any changes in its controlling shareholders since its establishment[17]. - The company has established a production capacity of 1,105 tons per day for edible mushrooms, with 745 tons for enoki mushrooms and 360 tons for button mushrooms, positioning it among the industry leaders[55]. - The company employs a factory-based production model, utilizing modern industrial facilities and advanced technology to create optimal growing conditions for mushrooms[45]. - The company has established a research and development center for mushroom biotechnology, equipped with advanced monitoring and data collection systems for production processes[50]. - The company has implemented a centralized procurement model to control costs and ensure stable production, focusing on quality and supplier capabilities[47]. - The company has adopted a dealer sales model, with product risk fully transferred to dealers upon acceptance of goods, and a deposit system for fixed dealers based on 5-10 days of sales[49]. - The company is focusing on a multi-variety development strategy centered on enoki and button mushrooms, enhancing its product quality and profitability[59]. Market and Industry Insights - The market for edible mushrooms is influenced by seasonal demand, with the second quarter typically being a low season for consumption[37]. - The price of enoki mushrooms saw a significant year-on-year increase starting in the third quarter of 2022 due to market supply and demand dynamics[35]. - The company is recognized as a "National Key Leading Enterprise in Agricultural Industrialization" and has established production bases across multiple provinces in China[39]. - The company is focusing on developing new hybrid strains of mushrooms, which is expected to enhance product quality and meet market demands[72]. - The company aims to diversify its product offerings by exploring new edible mushroom varieties suitable for industrial production and developing health products related to mushrooms[104]. Research and Development - The company has a total of 120 patents at the beginning of the reporting period, with 7 new patents added, and 67 patents expiring by the end of the reporting period[53]. - The company has invested 100 million yuan in R&D for new technologies aimed at improving product quality and sustainability[153]. - The company plans to enhance its research and development system for mushroom strains and establish an independent strain library to provide high-quality strains to domestic and international markets[104]. Governance and Compliance - The financial report is guaranteed to be true, accurate, and complete by the company's board of directors and management[5]. - The company emphasizes the importance of risk awareness among investors regarding forward-looking statements and performance forecasts[5]. - The company has established a transparent performance evaluation and incentive mechanism to enhance management efficiency[124]. - The company emphasizes investor relations management, actively engaging with investors through various communication channels[123]. - The company has revised several internal governance documents to strengthen its operational framework and compliance[125]. - The company maintains a complete and independent production system, with no reliance on the controlling shareholder for assets or operations[127]. Environmental Responsibility - The company is committed to environmental responsibility, following regulations such as the Environmental Protection Law and the Air Pollution Prevention Law[184]. - The company has obtained pollution discharge permits for its subsidiaries, with validity extending until December 2027 for some permits[185]. - The company has a wastewater treatment capacity of 600 m³/d, utilizing the A/O biological contact oxidation process, with all treated wastewater meeting the GB8978-1996 Class I discharge standards[187]. - The company has implemented a noise reduction strategy, achieving daytime noise levels of ≤60 dB(A) and nighttime levels of ≤50 dB(A), compliant with GB12348-2008 Class 2 standards[188]. - The company has established an emergency response plan for environmental incidents, which has been revised and filed with local environmental authorities[188]. Shareholder Engagement - The company held 3 shareholder meetings during the reporting period, ensuring compliance with relevant laws and regulations to protect the rights of minority shareholders[117]. - The participation ratio of investors in the first temporary shareholders' meeting of 2022 was 36.89%[133]. - The participation ratio of investors in the annual shareholders' meeting for 2021 was 37.04%[133]. - The total number of shares held by the chairman at the end of the reporting period was 1,324,432 shares[134]. - The company proposed a cash dividend of CNY 3.00 per 10 shares (including tax), with a total cash dividend amounting to CNY 117,876,243.90, representing 100% of the distributable profit[165][168]. Employee Management - The total number of employees at the end of the reporting period was 5,595, with 4,862 in production roles[158]. - The company has a comprehensive employee welfare program, including health management, safety training, and social insurance benefits[192]. - The employee stock ownership plan involved 255 employees holding a total of 9,000,000 shares, accounting for 2.21% of the company's total shares[170]. - The company has a performance bonus system that includes monthly assessments based on production output and annual evaluations based on operational goals[147]. Challenges and Risks - The company faces risks from industry competition leading to price declines, and it plans to leverage brand influence and product quality to enhance brand recognition and pricing power[108]. - The company is exposed to seasonal fluctuations in sales prices and profits, and it aims to diversify its product range and extend the edible mushroom industry chain to mitigate these risks[109]. - The company faced challenges in project implementation due to rising material costs and fluctuating sales prices, impacting overall profitability[95].